Simulations Plus (NASDAQ:SLP) Issues FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY25 earnings guidance on Thursday. The company provided earnings per share guidance of $1.07-1.20 for the period, compared to the consensus earnings per share estimate of $1.09. The company issued revenue guidance of $90-93 million, compared to the consensus revenue estimate of $90.40 million.

Simulations Plus Stock Performance

Simulations Plus stock traded down $0.95 during trading on Thursday, reaching $23.82. 351,146 shares of the company’s stock were exchanged, compared to its average volume of 175,219. Simulations Plus has a 52-week low of $23.00 and a 52-week high of $51.22. The firm has a market cap of $478.59 million, a price-to-earnings ratio of 59.55 and a beta of 0.89. The company’s 50-day moving average is $30.38 and its two-hundred day moving average is $30.38.

Simulations Plus (NASDAQ:SLP) last posted its earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.06. The business had revenue of $22.43 million during the quarter, compared to analyst estimates of $21.93 million. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The company’s revenue for the quarter was up 22.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.20 earnings per share. Analysts anticipate that Simulations Plus will post 1.09 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. William Blair restated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. KeyCorp upped their price objective on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. One analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Simulations Plus currently has a consensus rating of “Moderate Buy” and an average target price of $49.40.

Insider Buying and Selling at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the transaction, the director now owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. This trade represents a 0.58 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 19.40% of the stock is currently owned by insiders.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.